PT - JOURNAL ARTICLE AU - Alejandra Paniagua-Avila AU - Daniel Olson AU - Amy Connery AU - D. Mirella Calvimontes AU - Guillermo A. Bolanos AU - Molly M. Lamb AU - Desiree Bauer AU - Aida Ralda AU - Neudy Rojop AU - Eduardo Barrios AU - Andrea Chacon AU - Melissa Gomez AU - Paola Arroyave AU - Sara Hernandez AU - Maria Alejandra Martinez AU - Saskia Bunge-Montes AU - Alison Colbert AU - Kareen Arias AU - Garret Brazeale AU - Andrea Holliday AU - Kay M. Tomashek AU - Hana M. El Sahly AU - Wendy Keitel AU - Flor M. Munoz AU - Edwin J. Asturias TI - Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala AID - 10.1101/2022.05.12.22274987 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.12.22274987 4099 - http://medrxiv.org/content/early/2022/05/16/2022.05.12.22274987.short 4100 - http://medrxiv.org/content/early/2022/05/16/2022.05.12.22274987.full AB - During the course of the 2015-2017 outbreak of Zika virus (ZIKV) infection in the Americas, the emerging virus was recognized as a congenital infection that could damage the developing brain. As the Latin American ZIKV outbreak advanced, the scientific and public health community questioned if this newly recognized neurotropic flavivirus could affect the developing brain of infants and young children infected after birth. We report here the design, methods and rapid operationalization of a prospective natural history cohort study aimed at evaluating the potential neurological and neurodevelopmental effects of postnatal Zika virus infection in infants and young children, which had become epidemic in Central America. This study enrolled a cohort of 500 mothers and their infants, along with nearly 400 children 1.5-3.5 years of age who were born during the initial phase of the ZIKV epidemic in a rural area of Guatemala. Our solutions and lessons learned while tackling real-life challenges may serve as a guide to other researchers carrying out studies of emerging infectious diseases of public health priority in resource-constrained settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a National Institutes of Allergy and Infectious Diseases at the National Institutes of Health contract funding to the Vaccine and Treatment Evaluation Units (VTEUs) at Baylor College of Medicine HHSN272201300015I. Task Order No. HHSN27200013-16-0057.C1D1.0058. Agro-America and the Center for Global Health at the University of Colorado provided ongoing funding for the Center for Human Development and the Creciendos Sanos Program at FUNSALUD from where the study was implemented and operationalized. REDCap utilization was supported by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Boards of BCM, CU (COMIRB), and the Ministry of Public Health and Social Welfare (MSPAS) of Guatemala in May of 2017.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.